Abstract
Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Current Pharmaceutical Design
Title: The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Volume: 15 Issue: 1
Author(s): Christine L. Miller
Affiliation:
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Abstract: Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Export Options
About this article
Cite this article as:
Miller L. Christine, The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185805
DOI https://dx.doi.org/10.2174/138161209787185805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combinatorial Approaches to Iminosugars as Glycosidase and Glycosyltransferase Inhibitors
Combinatorial Chemistry & High Throughput Screening Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery
Protein & Peptide Letters New Vaccines and Delivery Strategies for Adult Immunization
Current Immunology Reviews (Discontinued) Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Synthesis, Biological Evaluation and Computational Study of New Quinoline Hybrids as Antitubercular Agent
Letters in Drug Design & Discovery Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Anti-Tuberculosis
Current Bioactive Compounds Editorial (Hot Topic: Emerging Therapeutic Targets in Inflammation and Allergy Drug Discovery from Patent Perspective)
Recent Patents on Inflammation & Allergy Drug Discovery State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Chemical Composition and Antibacterial Potential of Essential Oils from Artemisia Capillaris, Artemisia Nilagirica, Citrus Limon, Cymbopogon Flexuosus, Hedychium Spicatum and Ocimum Tenuiflorum
The Natural Products Journal Current Study of Natural Products for Medicinal Chemistry
Current Medicinal Chemistry An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Current Pharmaceutical Design Synthesis of Triazole Derivatives Manifesting Antimicrobial and Anti-Tubercular Activities
Mini-Reviews in Organic Chemistry Editorial (Thematic Issue: Enzymatic Studies in Medicinal Chemistry of Neglected Diseases)
Current Protein & Peptide Science Recent Advancement in the Diagnosis and Treatment of Leprosy
Current Topics in Medicinal Chemistry Antimicrobial Potential of Botanicals and Disease Control
The Natural Products Journal Nanoparticle as An Emerging Tool in Pulmonary Drug Delivery System
Micro and Nanosystems Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Virus Diagnostics on Microarrays
Current Pharmaceutical Biotechnology